IP Library › Granted Patent US 12,263,216
Granted Patent B2
US 12,263,216 · App. 17/232,597 · Granted Apr 1, 2025

Cancer antigens and methods

Inventors: George Kassiotis (London, GB); George Young (London, GB); Jan Attig (London, GB); Bram Snijders (London, GB); David Perkins (London, GB); Fabio Marino (London, GB); Nicola Ternette (London, GB)
Assignees: The Francis Crick Institute Limited; Enara Bio Limited
A61K39/39A61K39/4611A61K39/46449A61K39/464491A61P35/00C07K14/4748C07K16/32C12N5/0636C12N5/0639A61K2039/55505A61K2039/55522A61K2039/55538A61K2039/55561A61K2039/55566A61K2039/55572A61K2039/55577A61K2039/6031A61K2039/876A61K2239/57C07K2319/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,263,216
App. No.
17/232,597
Granted
Apr 1, 2025
Kind
B2
Abstract

There are disclosed inter alia polypeptides and nucleic acids encoding said polypeptides which are useful in the treatment, prevention and diagnosis of cancer, particularly melanoma, especially cutaneous melanoma and uveal melanoma.

Claims (10)

1. A composition comprising an isolated polypeptide and an immunostimulant selected from the group consisting of aluminum phosphate, saponins, immunostimulatory oligonucleotides, aminoalkyl glucosaminide 4-phosphates, lipopolysaccharides, 3-de-O-acylated monophosphoryl lipid A (3D-MPL), toll-like receptor 4 (TLR4) ligands, toll-like receptor 7 (TLR7) ligands, toll-like receptor 8 (TLR8) ligands, toll-like receptor 9 (TLR9) ligands, interleukin 12 (IL-12), and interferons, wherein:

the isolated polypeptide comprises the amino acid sequence selected from the group consisting of SEQ ID NO: 1, 11-14, 55-57 and 73-74.

2. A fusion protein comprising a first polypeptide and one or more additional polypeptides, wherein the first polypeptide comprises:

(i) the amino acid sequence selected from the group consisting of SEQ ID NO: 1, 11-14, 55-57 and 73-74;

(ii) a melanoma associated antigen;

iii) a universal CD4 helper epitope; or

(iv) an immunostimulant polypeptide selected from the group consisting of IL-12, interferons, and checkpoint blockade molecules,

wherein the first polypeptide and the one or more additional polypeptides are not the same.

3. A method of making the composition of claim 1 , the method comprising combining the immunostimulant with the isolated polypeptide, wherein:

the isolated polypeptide comprises the amino acid sequence selected from the group consisting of SEQ ID NO: 1, 11-14, 55-57 and 73-74.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 23, 2024
From: KASSIOTIS, GEORGE; YOUNG, GEORGE; ATTIG, JAN; SNIJDERS, BRAM; PERKINS, DAVID
To: THE FRANCIS CRICK INSTITUTE LIMITED
Reel/Frame 067193/0129 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 23, 2024
From: TERNETTE, NICOLA; MARINO, FABIO
To: ERVAXX LIMITED
Reel/Frame 067193/0135 →
CHANGE OF NAME Recorded Apr 23, 2024
From: ERVAXX LIMITED
To: ENARA BIO LIMITED
Reel/Frame 067193/0140 →
Priority Claims (1)
EP 18201634 · Oct 19, 2018 · regional
Continuity (2)
Continuation PCTGB2019052980 · Oct 18, 2019
Related Publication 20210353729A1 · Nov 18, 2021
References Cited (102)
US 7504490B1 · Weinstock et al. · 2009 [cited by applicant]
US 7745391B2 · Mintz · 2010 [cited by examiner]
US 20020082206A1 · Leach et al. · 2002 [cited by applicant]
US 20070072175A1 · Cooper et al. · 2007 [cited by applicant]
US 20070083334A1 · Mintz et al. · 2007 [cited by applicant]
US 20100136518A1 · Humer et al. · 2010 [cited by applicant]
US 20100285509A1 · Mayer et al. · 2010 [cited by applicant]
US 20110183924A1 · Mintz et al. · 2011 [cited by applicant]
US 20110217326A1 · Kudo et al. · 2011 [cited by applicant]
US 20140099324A1 · Wang-Johanning · 2014 [cited by applicant]
US 20150119265A1 · Perot et al. · 2015 [cited by applicant]
US 20160160295A1 · Chinnaiyan et al. · 2016 [cited by applicant]
US 20190322721A1 · Sonntag et al. · 2019 [cited by applicant]
US 20190351040A1 · Valiente et al. · 2019 [cited by applicant]
US 20210353729A1 · Kassiotis et al. · 2021 [cited by applicant]
US 20220211760A1 · Kassitois et al. · 2022 [cited by applicant]
US 20220213159A1 · Kassiotis et al. · 2022 [cited by applicant]
US 20220218807A1 · Kassiotis et al. · 2022 [cited by applicant]
US 20220220175A1 · Kassiotis et al. · 2022 [cited by applicant]
EP 1580263A1 · 2005 [cited by applicant]
JP 2003304877A · 2003 [cited by applicant]
WO WO0006598A1 · 2000 [cited by applicant]
WO 2001064835A2 · 2001 [cited by applicant]
WO 200175067A2 · 2001 [cited by applicant]
WO 2001077330A2 · 2001 [cited by applicant]
WO 2004038003A2 · 2004 [cited by applicant]
WO WO2005099750A1 · 2005 [cited by applicant]
WO 2006105642A1 · 2006 [cited by applicant]
WO WO2006103562A2 · 2006 [cited by applicant]
WO WO2006119527A2 · 2006 [cited by applicant]
WO 2007073478A2 · 2007 [cited by applicant]
WO WO2007109583A2 · 2007 [cited by applicant]
WO WO2007137279A2 · 2007 [cited by applicant]
WO 2008016356A2 · 2008 [cited by applicant]
WO 2008118258A2 · 2008 [cited by applicant]
WO 2009026116A2 · 2009 [cited by applicant]
WO 2009039244A2 · 2009 [cited by applicant]
WO 2013033333A1 · 2013 [cited by applicant]
WO 2013040142A2 · 2013 [cited by applicant]
WO 2014004385A2 · 2014 [cited by applicant]
WO 2017097699A1 · 2017 [cited by applicant]
WO 2020079448A1 · 2020 [cited by applicant]
WO 2020260897A1 · 2020 [cited by applicant]
WO 2020260898A2 · 2020 [cited by applicant]
WO 2021005338A2 · 2021 [cited by applicant]
WO 2021005339A1 · 2021 [cited by applicant]
Attermann et al., “Human endogenous retroviruses and their implication for immunotherapeutics of cancer,” Ann Oncol. Nov. 1, 2018;29(11):2183-2191. [cited by applicant]
Attig et al., “Physiological and Pathological Transcriptional Activation of Endogenous Retroelements Assessed by RNA-Sequencing of B Lymphocytes,” Front Microbiol. Dec. 12, 2017;8:2489. [cited by applicant]
Bannert et al., “HERVs new role in cancer: from accused perpetrators to cheerful protectors,” Front Microbiol. Feb. 13, 2018;9:178. [cited by applicant]
Bulik-Sullivan et al., “Deep learning using tumor HLA peptide mass spectrometry datasets improves neoantigen identification,” Nat Biotechnol. Jan. 2019;37(1):55-63. [cited by applicant]
Cegolon et al., “Human endogenous retroviruses and cancer prevention: evidence and prospects,” BMC Cancer. Jan. 3, 2013;13:4. [cited by applicant]
Escudier et al., “Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: results of thefirst phase I clinical trial,” J Transl Med. Mar. 2, 2005;3:10. [cited by applicant]
Ferrucci et al., “Newly identified tumor antigens as promising cancer vaccine targets for malignant melanoma treatment,” Curr Top Med Chem. 2012; 12(1):11-31. [cited by applicant]
“ [cited by applicant]
“ [cited by applicant]
Jayson et al., “Ovarian cancer,” Lancet. Oct. 11, 2014;384(9951): 1376-88. [cited by applicant]
“Macaca fuscata fuscata DNA, clone: MSB2-228H05_R, genomic survey sequence,” EBI Accession No. AG759599. [cited by applicant]
PCT International Search Report and Written Opinion from PCT/US2021/028029, dated Aug. 9, 2021. [cited by applicant]
Schuster et al., “The immunopeptidomic landscape of ovarian carcinomas,” Proc Natl Acad Sci U S A. Nov. 14, 2017;114(46):E9942-E9951. [cited by applicant]
“SubName: Full = Acetyltransferase {ECO : 0000313 | EMBL : EFE74977.2},” EBI Accession No. UNIPROT: D6AHI5. [cited by applicant]
Ternette et al., “Immunopeptidomic Profiling of HLA-A2-Positive Triple Negative Breast Cancer Identifies Potential Immunotherapy Target Antigens,” Proteomics. Jun. 2018;18(12):e1700465. [cited by applicant]
“UI-H-DPO-avc-g-14-0-UI.s1 NCI_CGAP_Fs1 [cited by applicant]
UniParc—UPI00060150B7. [cited by applicant]
Yin et al., “Immature dendritic cell-derived exosomes: a promise subcellular vaccine for autoimmunity,” Inflammation. Feb. 2013;36(1):232-40. [cited by applicant]
PCT International Search Report and Written Opinion from PCT/GB2021/050940, dated Aug. 3, 2021. [cited by applicant]
Pandiani, Charlotte, et al. “Focus on cutaneous and uveal melanoma specificities.” Genes & development 31.8 (2017):724-743. [cited by applicant]
Attig et al., Supplemental Material—“LTR retroelement expansion of the human cancer transcriptome and immunopeptidome revealed by de novo transcript assembly,” Genome Res. Oct. 2019;29(10): (160 pages). [cited by applicant]
Acha-Orbea, et al., “Superantigens of Mouse Mammary Tumor Virus,” Ann Rev Immunol. 13: 459-486 (1995). [cited by applicant]
Andersson et al., “Expression of Human Endogenous Retrovirus ERV3 (HERV-R) mRNA in Normal and Neoplastic Tissues,” International Journal of Oncology 12(2): 309-322 (1998). [cited by applicant]
Aspergillus fumigatus ORF amino acid sequence SEQ ID No. 31732 EBI Accession No. GSP: AWP60286. [cited by applicant]
Attig et al., “LTR Retroelement Expansion of the Human Cancer Transcriptome and Immunopeptidome Revealed by De Novo Transcript Assembly,” Genome Res. 10: 1578-1590 (2019). [cited by applicant]
Aung et al., “Expression of New York Esophageal Squamous Cell Carcinoma-1 in Primary and Metastatic Melanoma,” Hum Pathol. 45(2): 259-267 (2014). [cited by applicant]
Babaian et al., “Endogenous Retroviral Promoter Exaptation in Human Cancer.” Mobile DNA 7(1): 1-21 (2016). [cited by applicant]
Bassani-Sternberg et al., “Direct Identification of Clinically Relevant Neoepitopes Presented on Native Human Melanoma Tissue by Mass Spectrometry,” Nature Communications 7(1): 1-16 (2016). [cited by applicant]
Cherkasova et al., “Endogenous Retroviruses as Targets for Antitumor Immunity in Renal Cell Cancer and Other Tumors,” Front Oncol. 3: 243 (2013). [cited by applicant]
“DNA fragments of a human Tox gene, 47247” EBI Accession No. GSN: ARC03196. [cited by applicant]
Gigoux et al., “Refusing to TAP Out: 16 New Human TEIPPs Identified,” The Journal of Experimental Medicine 215(9): 2233 (2018). [cited by applicant]
Hoyos et al., “Cancer-Specific Splicing Changes and the Potential for Splicing-Derived Neoantigens,” Cancer Cell 34(2): 181-183 (2018). [cited by applicant]
Human 0RF553 EBI Accession No. GSP: ABP64183. [cited by applicant]
Human derived non-coding RNA CAT2186.2 SEQ: 1274 EBI accession No. GSN: BCQ57982. [cited by applicant]
Human derived non-coding RNA MEAT62.1, SEQ: 1895 EBI Accession No. GSN: BCQ58603. [cited by applicant]
Humer et al., “Identification of a Melanoma Marker Derived from Melanoma-Associated Endogenous Retroviruses,” Cancer Research 66(3): 1658-1663 (2006). [cited by applicant]
Hurst et al., “Activation of the Innate Immune Response by Endogenous Retroviruses,” J Gen Virol., 96(6): 1207-1218 (2015). [cited by applicant]
Kahles et al., “Comprehensive Analysis of Alternative Splicing Across Tumors From 8,705 Patients,” Cancer Cell 4(2): 211-224 (2018). [cited by applicant]
Kassiotis et al., “Immune Responses to Endogenous Retroelements: Taking the Bad With the Good,” Nat Rev Immunol., 16(4): 207-219 (2016). [cited by applicant]
Katoh et al., “Association of Endogenous Retroviruses and Long Terminal Repeats With Human Disorders,” Front Oncol. 3: 234 (2013). [cited by applicant]
Kershaw et al., “Immunization Against Endogenous Retroviral Tumor-Associated Antigens,” Cancer Research 61(21): 7920-7924 (2001). [cited by applicant]
Laumont et al., “Noncoding Regions Are The Main Source of Targetable Tumor-Specific Antigens,” Sci Transl Med. 10: 470 (2018). [cited by applicant]
Lauss et al., “Mutational and Putative Neoantigen Load Predict Clinical Benefit of Adoptive T Cell Therapy in Melanoma,” Nature Communications 8(1): 1-11 (2017). [cited by applicant]
Lock et al., “Distinct isoform of FABP7 revealed by screening for retroelement-activated genes in diffuse large B-cell lymphoma.” Proceedings of the National Academy of Sciences 111.34 (2014): E3534-E3543. [cited by applicant]
Mangeney et al., “The Full-Length Envelope of an HERV-H Human Endogenous Retrovirus has Immunosuppressive Properties.” Journal of General Virology 82(10): 2515-2518 (2001). [cited by applicant]
Marijt et al., “Identification of Non-Mutated Neoantigens Presented by TAP-Deficient Tumors,” Journal of Experimental Medicine 215(9): 2325-2337 (2018). [cited by applicant]
Ribas et al., “Cancer Immunotherapy Using Checkpoint Blockade,” Science 359(6382): 1350-1355 (2018). [cited by applicant]
Ruprecht et al., “Endogenous Retroviruses and Cancer,” Cell Mol Life Sci., 65(21): 3366-3382 (2008). [cited by applicant]
Sacha et al., “Vaccination With Cancer-and HIV Infection-Associated Endogenous Retrotransposable Elements is Safe and Immunogenic,” The Journal of Immunology 189(3): 1467-1479 (2012). [cited by applicant]
Schiavetti et al., “A Human Endogenous Retroviral Sequence Encoding an Antigen Recognised on Melanoma by Cytolytic T Lymphocytes,” Cancer Res. 62(19): 5510-5516 (2002). [cited by applicant]
Slansky et al., “Enhanced Antigen-Specific Antitumor Immunity with Altered Peptide Ligands that Stabilize the MHC-Peptide-TCR Complex,” Immunity 13(4): 529-538 (2000). [cited by applicant]
Wold et al. “Adenovirus Vectors for Gene Therapy, Vaccination and Cancer Gene Therapy,” Current Gene Therapy 13(6): 421-433 (2013). [cited by applicant]
Smart et al., “Intron Retention is a Source of Neoepitopes in Cancer,” Nature Biotechnology 36(11): 1056-1058 (2018). [cited by applicant]
Acetyltransferase EBI Accession No. UNIPROT: D6AHI5. [cited by applicant]
Wang-Johanning et al., “Detecting the Expression of Human Endogenous Retrovirus E Envelope Transcripts in Human Prostate Adenocarcinoma,” Cancer 98:(1): 187-197 (2003). [cited by applicant]
Yossef et al., “Enhanced Detection of Neoantigen-Reactive T Cells Targeting Unique and Shared Oncogenes for Personalized Cancer Immunotherapy,” JCI Insight 3(19): (2018). [cited by applicant]
Cited By (1)
US 12,680,105